Roelofs Kelsey A, Fabian Ido Didi, Arora Amit K, Cohen Victoria M L, Sagoo Mandeep S
Ocular Oncology Service, Moorfields Eye Hospital, London, United Kingdom.
Ocular Oncology Service, Moorfields Eye Hospital, London, United Kingdom; Goldschleger Eye Institute, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Tel-Aviv, Israel.
Ophthalmol Retina. 2021 May;5(5):468-478. doi: 10.1016/j.oret.2020.08.019. Epub 2020 Sep 2.
To report the long-term outcomes of patients with small, pigmented, posteriorly located choroidal melanoma undergoing primary treatment using photodynamic therapy (PDT) with verteporfin at the London Ocular Oncology Service.
Retrospective, interventional, consecutive case series.
All patients undergoing primary treatment using PDT with verteporfin from April 2014 to December 2015 and followed until December 2019.
This is a long-term follow-up study of the same cohort of patients previously reported by our group in 2017 and 2018.
Local tumor control, visual outcomes, and metastasis-free survival.
Twenty-six patients were included with a mean (± standard deviation) age and tumor thickness of 62 ± 14 years and 1.3 ± 0.5 mm, respectively. Tumors were posteriorly located (mean distance to optic nerve and fovea = 2.0 ± 2.2 mm and 1.6 ± 1.5 mm, respectively), and the majority were fully pigmented (73%). Overall, patients were followed for a median (interquartile range [IQR], range) of 49.5 (15.3, 7.0-66.0) months from first PDT to last follow-up. Over the course of this study, 14 of 26 (54%) have developed a local recurrence at a median of 20.0 months (20.5, 4.7-60.9 months). The most common pattern of recurrence was an isolated increase in basal dimensions (9/14; 64%). Median (IQR) final logarithm of the minimum angle of resolution visual acuity of the whole cohort was 0.2 (0.5). The only statistically significant difference in baseline and outcome characteristics between treatment failures and nonfailures was the distance to the fovea (median [IQR], 0.5 [1.3] vs. 2.5 [2.8]; P = 0.002) and final logarithm of the minimum angle of resolution visual acuity (median [IQR], 0.50 [0.80] vs. 0.00 [0.14]; P = 0.002), respectively.
Although treatment of small pigmented posterior choroidal melanoma with PDT effectively preserves visual acuity, 5-year treatment-success calculated by Kaplan-Meier analysis was only 38.4%. Recurrences after PDT tend to occur along the tumor edges, often with minimal increase in thickness. Given the substantial risk of treatment failure, primary PDT with vertepofrin is recommended in exceptional cases of choroidal melanoma, for which other treatments with greater tumor control are not a feasible option.
报告在伦敦眼肿瘤服务中心接受维替泊芬光动力疗法(PDT)进行初始治疗的小的、色素性、位于后部的脉络膜黑色素瘤患者的长期预后。
回顾性、干预性、连续病例系列研究。
2014年4月至2015年12月期间接受维替泊芬PDT初始治疗并随访至2019年12月的所有患者。
这是对我们团队在2017年和2018年报告的同一组患者的长期随访研究。
局部肿瘤控制、视力结果和无转移生存期。
纳入26例患者,平均(±标准差)年龄和肿瘤厚度分别为62±14岁和1.3±0.5mm。肿瘤位于后部(距视神经和黄斑的平均距离分别为2.0±2.2mm和1.6±1.5mm),大多数为完全色素性(73%)。总体而言,患者从首次PDT到最后一次随访的中位(四分位间距[IQR],范围)时间为49.5(15.3,7.0 - 66.0)个月。在本研究过程中,26例中有14例(54%)出现局部复发,中位复发时间为20.0个月(20.5,4.7 - 60.9个月)。最常见的复发模式是基底尺寸单独增加(9/14;64%)。整个队列最终最小分辨角视力对数的中位(IQR)值为0.2(0.5)。治疗失败组与未失败组在基线和结局特征方面唯一具有统计学意义的差异分别是距黄斑的距离(中位[IQR],0.5[1.3]与2.5[2.8];P = 0.002)和最终最小分辨角视力对数(中位[IQR],0.50[0.80]与0.00[0.14];P = 0.002)。
尽管用PDT治疗小的色素性后部脉络膜黑色素瘤可有效保留视力,但通过Kaplan-Meier分析计算的5年治疗成功率仅为38.4%。PDT后复发往往发生在肿瘤边缘,通常厚度增加最小。鉴于治疗失败风险较大,维替泊芬初始PDT仅在脉络膜黑色素瘤的特殊情况下推荐使用,对于这些情况,其他具有更好肿瘤控制效果的治疗方法不可行。